Reversal of Right Ventricular Steatosis in Pulmonary Hypertension

Withdrawn before enrolling · Not applicable

Conditions studied: Pulmonary; Hypertension, Steatosis, Right Ventricular Failure

In brief

The goal of this study is to elucidate the relationship between myocardial right ventricular triglyceride content (steatosis) and right ventricular dysfunction in participants with pulmonary hypertension, and investigate reversibility of this phenotype with omega-3 fatty acid treatment.

Key facts

Study ID

NCT02966899

Run by

Wen-Chih Wu

People needed

0

Starts

2016-11-01

Expected to finish

2017-07-01

Last updated by the study team

2023-12-13

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult men and women > 30 years of age with a diagnosis of pulmonary hypertension (defined as mean pulmonary arterial pressure ≥25 mmHg at rest on right heart catheterization)

You may not qualify if…

• Contraindication to MRI (e.g., metallic hazards or allergy to gadolinium)
• Renal dysfunction (eGFR < 60 ml/min/1.73m2 as estimated by the Modified Diet in Renal Disease formula)
• High risk features for nephrogenic systemic fibrosis (solitary kidney or prior renal transplant)
• Active pregnancy or breastfeeding (determined by urinary pregnancy test before CMR)
• Weight > 550 lb or waist diameter > 70 cm (limits for our Siemens Verio CMR system)
• Fish Allergy

Where it is running

• Providence VA Medical Center — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.